SAMARTH is an innovative life sciences company that researches, develops, manufactures and markets a broad range of life saving Critical Care & other drugs and committed to deliver better health through superior products.
Our Vision is to emerge as an Innovative Premier Health Care company, “Adding Life to Life”, by delivering right quality products to medical fraternity with the highest level of operational excellence. Samarth’s unique focus is to bring innovative proprietary pharmaceuticals while addressing unmet medical needs to serve the patients, the ultimate customer.
We have earned respect and customer loyalty through therapeutic area expertise and understanding of global and local regulatory environments. We aim at exponential growth through innovation, expansion into new therapeutic areas. We are market and technology driven company with strong R & D base for orphan and lifesaving healthcare products.
The group’s origin can be traced to 1963 when it was founded by Mr. Gunwantlal Shah, a first-generation entrepreneur with humble beginnings. Today, Samarth has grown into multi-locational, multi-dimensional company.
Our flagship brands ADRENOR, ATRAPURE, CAPRIN, CPRESSIN, DISTINON, DEXMEDINE, ENDACE, ENDOCRYL, EUTRIG, EUROLIDE DEPOT, FLORICOT, KENADION, HISONE, LOBET, LOWCAP, MUCOMIX, POLY B, TERLISTAT, UROTONE etc., have gained wide credibility and acceptance among the medical fraternity and have become brand leaders in their respective segments. Exports are also thriving, and our products find place on the shelves of markets in South America, U.K, South East Asian countries and many African states. Many Countries import our products under special imports.
Our products are manufactured at cGMP facilities with cutting edge technology.
Be an Innovative Global Healthcare Company adding Life to Life.
To become a Rs.10 Billion Company by 2020. We have a proud Heritage passionately committed to providing innovative and differentiated products, that improve people’s life and make India proud.
SAMARTH has aggressive strategies and growth plans and aspires to collaborate with global pharmaceutical companies in the areas of:
- Development and manufacture of biologics in genetically modified organisms; starting with protein expression through clinical trials till eventual commercialization.
- Established strengths in development of drugs using Novel Drug Delivery Systems (NDDS) like microspheres, liposomes, micelles and emulsions.
- Expanding global presence for company’s current portfolio including orphan drugs with suitable product dossiers and Drug Master Files (DMF).
- Alliances for contract manufacturing, and joint ventures
- In-licensing of registered formulations (including nutritional) for Animal Health Business.
SAMARTH has proven track record in building strong, collaborative relationships. We have identified, developed and commercialised promising new technologies and products that align with our core franchises. These partnerships have been key in contributing to our growth and becoming a premier health care company. Within a short span, SAMARTH has firmly established its international presence in many developing and advanced western countries.
Year Major Events 1997 Incorporation of “SOHINI HOLDINGS & FINANCE PRIVTE LIMITED”. 2004 Change of company’s name to “SAMARTH LIFE SCIENCES PVT LTD” with change in Objects clause. 2004 Creation of marketing teams and setting up of All India Distribution network. 2004
Launch of “Ancard” Sales & Marketing Teams focusing in the management of shock, hypertensive management in critical care, wide array of Anaesthetic agents and anticoagulants therapy. Launch of “Samgen” Sales & Marketing Teams focusing super specialties like Neuro, Gastro, Surgeons & Uros & Paediatric Cardiologist.
2005 Launch of “Onquest” Sales & Marketing Teams focusing world class quality products at affordable price to improve QOL and survival of cancer patients. 2006 Setting up of ‘State of the art’ manufacturing unit at Baddi for manufacture of Tablets, Capsules & Injectables (Liquid & Powder). 2008 Setting up of dedicated facility for manufacture of anti-cancer products and highly potent hormonal range of products. 2008
Amongst only 5 pharma companies manufacturing anti-cancer products. Amongst only 3 pharma companies in India to manufacture of Lipolyzed anti-cancer formulations with in-house technology.
2009 Awarded “Technically & Scientifically most advanced Biotech Company” by President of India at India Leadership Conclave, New Delhi. 2010 Awarded “The Emerging Company of the Year” by The Governor of Maharashtra. 2010
Launch of “Critigen” Sales & Marketing Teams focusing critical infections in critical care Launch of “Eugenic” Sales & Marketing Teams focusing on providing world class comprehensive infertility treatment.
2012 Setting up and inauguration of ultra-modern bio-technology facility at Vasantnarasapur, Tumkur (Dist) near Bangalore, Karnataka. 2014 Launch of “Samkam” Institutional Business Team to focus on Government & Semi-Government Institutions & Government run Hospitals. 2016 Launch of “WHC” Women’s Healthcare Sales & Marketing Team focusing innovative products directed towards myriad gynaecological conditions . 2016-17
Launch of “Zuvets” Animal Health Sales & Marketing Team focusing on innovative solutions for Dairy business. Joint Venture with Chinese Company for manufacture of Biological APIs.
Modernization of Unit 2, Baddi Unit. Launch of “Urology” Sales & Marketing Team focusing on Uro Specialty. Entry into “Malaysia” – Started construction of Manufacturing Plant.